Wen-Chun Liu

TL;DR: It is proposed that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.

TL;DR: The findings of a World Health Organization expert working group that is developing animal models to test vaccines and therapeutic agents for the treatment of COVID-19, and their relevance for preclinical testing, are reviewed.

TL;DR: A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).

TL;DR: The first in-depth characterization of the host transcriptional response to SARS-CoV-2 and other respiratory infections through in vitro, ex vivo, and in vivo model systems suggest that the unique transcriptional signature of this virus may be responsible for the development of COVID-19.

TL;DR: In this paper, a microfluidic bronchial-airway-on-a-chip line was used to model the human airway epithelium and pulmonary endothelium to model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells.